Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a ...

The newly recommended dosing schedule significantly lowered ARIA-E rates compared to the original dosing schedule, adding to the established safety profile of the treatment INDIANAPOLIS, ...

The U.S. Food and Drug Administration approved changing the prescribing information for Eli Lilly's Alzheimer's drug Kisunla to allow more gradual dosing to lower the risk of a potentially dangerous ...

Eli Lilly and Company (LLY) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has approved a label ...

David Ajayi, a Nigerian-born data science leader, is redefining clinical research infrastructure and digital health systems ...

The stocks listed here each increased their dividend payments by more than 10% recently. When you think of a great dividend ...

According to UBS, the company’s next major driver is the SURPASS cardiovascular outcomes trial. The bank added that Eli Lilly ...

Eli Lilly and Company (NYSE: LLY) is one of the 13 best blue-chip stocks to buy, according to analysts. On June 30, RBC ...

Investing in attractive dividend growth stocks can lead to superior long-term returns. The two healthcare companies below ...

The FDA will allow a new dosing schedule for Eli Lilly’s Alzheimer’s drug Kisunla that could lessen a known side effect of ...